Autobahn Therapeutics wanted to take advantage of the neuropsychiatric benefits observed with thyroid hormone therapy without systemic side effects, so the company used its proprietary technology for oral drugs that can cross the blood-brain barrier to develop a thyromimetic as an adjunctive treatment for depression. Now, with $100m in series C venture capital in hand, Autobahn plans to initiate Phase II clinical trials later this year for lead drug candidate ABX-002.
Autobahn Speeds Lead Drug Into Phase II With $100m In Fresh Cash
Second Candidate Headed For Phase I In 2025
Autobahn raised $100m in series C venture capital to take its oral, brain-penetrant thyromimetic ABX-002 into Phase II studies in major depressive disorder and bipolar disorder depression.
More from Financing
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
• By
A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.